ES2821821T3 - Derivados de tetrahidroisoquinolina - Google Patents

Derivados de tetrahidroisoquinolina Download PDF

Info

Publication number
ES2821821T3
ES2821821T3 ES15775688T ES15775688T ES2821821T3 ES 2821821 T3 ES2821821 T3 ES 2821821T3 ES 15775688 T ES15775688 T ES 15775688T ES 15775688 T ES15775688 T ES 15775688T ES 2821821 T3 ES2821821 T3 ES 2821821T3
Authority
ES
Spain
Prior art keywords
methyl
dihydroisoquinolin
dichlorophenyl
ethanone
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15775688T
Other languages
English (en)
Spanish (es)
Inventor
Anne Valade
Eric Jnoff
Ali Ates
Pierre Burssens
David Skolc
Zara Sands
Benoît Mathieu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Application granted granted Critical
Publication of ES2821821T3 publication Critical patent/ES2821821T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
ES15775688T 2014-10-08 2015-10-06 Derivados de tetrahidroisoquinolina Active ES2821821T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
ES2821821T3 true ES2821821T3 (es) 2021-04-27

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15775688T Active ES2821821T3 (es) 2014-10-08 2015-10-06 Derivados de tetrahidroisoquinolina

Country Status (18)

Country Link
US (1) US10105359B2 (show.php)
EP (1) EP3204359B1 (show.php)
JP (1) JP6622299B2 (show.php)
CN (1) CN107001278B (show.php)
BR (1) BR112017007123B1 (show.php)
CA (1) CA2963951C (show.php)
CY (1) CY1123417T1 (show.php)
DK (1) DK3204359T3 (show.php)
EA (1) EA035544B1 (show.php)
ES (1) ES2821821T3 (show.php)
HR (1) HRP20201469T1 (show.php)
HU (1) HUE050664T2 (show.php)
LT (1) LT3204359T (show.php)
PL (1) PL3204359T3 (show.php)
PT (1) PT3204359T (show.php)
RS (1) RS60933B1 (show.php)
SI (1) SI3204359T1 (show.php)
WO (1) WO2016055479A1 (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43677A (fr) * 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
EA036137B1 (ru) * 2016-04-13 2020-10-02 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
DK3717025T3 (da) * 2017-12-01 2021-11-22 UCB Biopharma SRL Billeddannende midler
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
EP3993795A1 (en) * 2019-07-01 2022-05-11 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
WO2021001288A1 (en) * 2019-07-01 2021-01-07 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
JP2023522980A (ja) * 2020-04-24 2023-06-01 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Nurr1受容体調節因子及びその使用
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
SI4200280T1 (sl) * 2020-10-07 2024-04-30 Eli Lilly And Company Derivati fenil-3,4-dihidroizokvinolin-2(1H)-il-etan-1-ona kot pozitivni alosterični modulatorji dopamin D1 receptorja
CA3198635A1 (en) * 2020-12-03 2022-06-09 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
CN116601161A (zh) * 2020-12-18 2023-08-15 Ucb生物制药有限责任公司 2-(3,5-二氯-1-甲基-吲唑-4-基)-1-[(1s,3r)-3-(羟基甲基)-5-(1-羟基-1-甲基-乙基)-1-甲基-3,4-二氢-1h-异喹啉-2-基]乙酮的前药
WO2022129303A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
CA3202993A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
US20240299375A1 (en) 2021-03-08 2024-09-12 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
KR20230154968A (ko) 2021-03-09 2023-11-09 일라이 릴리 앤드 캄파니 파킨슨병 진행을 늦추기 위한 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
MXPA04005988A (es) 2001-12-19 2004-09-27 Lundbeck & Co As H 3,4-dihidro-1h-isoquinolin-2-il-derivados.
EP1749001B1 (en) * 2004-04-29 2010-03-03 Aventis Pharmaceuticals, Inc. 3-piperidinylisochroman-5-ols as dopamine agonists
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3

Also Published As

Publication number Publication date
CA2963951C (en) 2023-02-28
WO2016055479A1 (en) 2016-04-14
CN107001278B (zh) 2020-11-24
US10105359B2 (en) 2018-10-23
HUE050664T2 (hu) 2020-12-28
US20170304292A1 (en) 2017-10-26
EA201790785A1 (ru) 2017-10-31
JP6622299B2 (ja) 2019-12-18
DK3204359T3 (da) 2020-09-14
PL3204359T3 (pl) 2021-03-22
EP3204359A1 (en) 2017-08-16
JP2017530185A (ja) 2017-10-12
BR112017007123B1 (pt) 2023-01-31
HRP20201469T1 (hr) 2020-12-11
PT3204359T (pt) 2020-09-24
SI3204359T1 (sl) 2020-10-30
EA035544B1 (ru) 2020-07-03
EP3204359B1 (en) 2020-07-01
BR112017007123A2 (pt) 2017-12-19
CA2963951A1 (en) 2016-04-14
RS60933B1 (sr) 2020-11-30
CN107001278A (zh) 2017-08-01
CY1123417T1 (el) 2021-12-31
LT3204359T (lt) 2020-10-12

Similar Documents

Publication Publication Date Title
ES2821821T3 (es) Derivados de tetrahidroisoquinolina
ES2955037T3 (es) Nuevos compuestos heterocíclicos
CN109715613B (zh) 杂环化合物
CN113214287B (zh) Hpk1抑制剂及其使用方法
JP6529085B2 (ja) 複素環化合物
BR112021008986A2 (pt) composto, composto da fórmula, composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratar o câncer, para regular a atividade de uma proteína mutante g12c k-ras, para inibir a proliferação de uma população de células, para tratar um distúrbio mediado, para preparar uma proteína e para inibir metástase de tumor e uso
JP2022515879A (ja) 複素環式化合物、中間体、その製造方法及び応用 本願は、出願日が2018年12月29日の中国特許出願cn 201811642319、出願日が2019年05月24日の中国特許出願cn201910440214.3及び出願日が2019年10月24日の中国特許出願cn201911016158.7に基づいて優先権を主張する。また、上記中国特許出願の全文は本願に援用される。
JP2022516469A (ja) ユビキチン特異的プロテアーゼ1を阻害するための組成物
TW201710255A (zh) 雜環化合物
EA021126B1 (ru) Замещенные изохинолиноны и хинализолиноны
BR112017023147B1 (pt) Derivados de azabenzimidazóis, seus usos como moduladores do receptor de ampa e composições farmacêuticas
JPWO2017069173A1 (ja) 複素環化合物
CN105745209A (zh) 三唑并吡啶化合物、组合物及其使用方法
CN112334450A (zh) 作为RORγt的调节剂的苯基和吡啶基取代的咪唑
CN108884050A (zh) 四氢异喹啉衍生物
ES2960408T3 (es) Compuesto heterocíclico y su uso como modulador alostérico positivo del receptor M1 muscarínico colinérgico
JP2022540825A (ja) Mcl-1阻害剤としての大環状スピロ環誘導体
WO2019189555A1 (ja) 複素環化合物
ES2729490T3 (es) Derivados de isoindolina
JP2022544700A (ja) 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
ES3001126T3 (es) Derivados de 1-((1H-pirazol-4-il)metil)-3-(fenil)-1,3-dihidro-2H-imidazol-2-ona y compuestos relacionados como antagonistas de GPR139 para el tratamiento de la depresión
BR112019026096A2 (pt) composto, medicamento, métodos para modulação alostérica positiva do receptor muscarínico colinérgico m1 e para a profilaxia ou o tratamento de constipação, e, uso do composto
RU2809257C2 (ru) Новые гетероциклические соединения
HK40057478B (zh) Hpk1抑制剂及其使用方法
KR20230104163A (ko) 암 치료용 벤조[h]퀴나졸린-4-아민 및 티에노[3,2-h]퀴나졸린-4-아민 유도체